Immune checkpoint inhibitor therapy in advanced cervical cancer: Deepened response with prolonged treatment and repeat response to re-initiation of therapy.

Immune checkpoint inhibitors (ICI) were approved in June 2018 for second line treatment of metastatic cervical cancer after progression on platinum-based chemotherapy. A cohort of 10 patients who received single agent ICI as second line treatment was examined, with an initial analysis published in July 2021. We performed an updated review of the duration of treatment response, outcome off treatment after 2 years of therapy, and outcome after re-initiation of ICI.

The prevalence of asymptomatic COVID-19 infection in cancer patients. A cross-sectional study at a tertiary cancer center in New York City.

Objective: Several factors raise concern for increased risk of COVID-19 in cancer patients. While there is strong support for testing symptomatic patients. The benefit of routine testing of asymptomatic patients remains contentious.

Brain metastasis in two patients with stage IA papillary serous carcinoma of the uterus.

We report two cases of brain metastasis in patients initially diagnosed with extremely early stage UPSC after extensive staging surgery. They did not receive either adjuvant chemotherapy or adjuvant pelvic or vaginal cuff radiation. At the same time that these patients were diagnosed with systemic metastasis, they both had a local "drop" metastasis in the vulva or the vaginal cuff.

A Chinese version of the Spiritual Needs Assessment for patients survey instrument.

Context: Unmet spiritual needs have been associated with decreased patient ratings of quality of care, satisfaction, and quality of life. Few instruments exist to measure spiritual needs particularly among non-English speaking patients in the U.S.